Notably, CD8+ IFNγ+ T cell-mediated anti-tumor response poses one of the mechanisms of action of doxorubicin therapy as demonstrated by us previously (62) and is of critical importance for the anti-PD-L1 immune checkpoint therapy (63, 64). Here, CD8A is linked to neoplasm.